



## **Next Science to strengthen senior leadership presence in US**

**Sydney, Australia, Friday, 27 May 2022:** Next Science Limited (ASX:NXS) (**Next Science/Company**) advises that Managing Director and Chief Executive Officer (**CEO**), Judith Mitchell, has announced her intention to retire as CEO of Next Science before 30 June 2023. Ms Mitchell's successor will be based in the US in Next Science's Jacksonville, Florida offices.

Ms Mitchell temporarily moved to the US in October. Ms Mitchell has since advised the Board that having been on the ground in the US for the last six (6) months, her assessment is that the business would benefit from the CEO being located in the US. Ms Mitchell further advised that she was not, for personal reasons, able to make a long-term commitment to reside in the US and expressed her wish to return to Sydney.

Following in depth discussions with the CEO which have included consideration of the Company's medium to long term strategic plans, the Board supports the CEO's assessment.

Ms Mitchell is committed to supporting an orderly transition to a new CEO and will continue as CEO, located in the US, until a successful transition has been achieved.

The Board is confident that the relocation of the CEO role to the US will benefit patients, healthcare professionals, employees, partners and shareholders. The ASX listing of the Company, decision-making base and financial control centre will remain in Sydney under the direction and control of the Board of Directors.

Next Science Chair, Mark Compton, praised Ms Mitchell on her leadership contribution.

"Whilst Judy will remain CEO for some time yet, I would like to thank her, on behalf of the Board and shareholders, for her leadership. Judy's contribution since her appointment in 2017 has included more than tripling revenues from US\$2.84M in FY18 to US\$8.94M in FY21 and leading a successful listing of the Company on the ASX in 2019.

The Board is grateful to Judy for allowing it the time required to identify an appropriate successor and will commence a global search immediately"

Managing Director Judith Mitchell said: "I would like to thank our Chair, our Board, and our shareholders for their support throughout my time as CEO. I would like to particularly thank Next Science's outstanding employees who come to work each day aligned with and dedicated to our mission to heal people and save lives. It has been a privilege to serve as the CEO of Next Science.

Until I step down, I will remain fully focused and driven to execute the Company's growth strategy and to ensuring that my successor is well placed to achieve success as the new CEO of Next Science. At that point, I will return to Sydney and enjoy supporting Next Science as a long- term shareholder."

Approved and authorised by the Board.

Further information:

**Judith Mitchell**

Managing Director, Next Science Limited

Phone: +61 2 9375 7989

Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Pegasus Advisory

Phone: +61 400 248 080

Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

**About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio™ technology. Website: [www.nextscience.com](http://www.nextscience.com).